Audax Private Equity Announces the Recapitalization of Corrona
Summary
The Company, founded in 2000 and headquartered in Waltham, MA, provides real world evidence through syndicated registry data and analysis services. We are excited to start a new chapter in the history of Corrona.” He continued, “Audax has complementary assets in the healthcare space we can partner with, and also supports Corrona’s commitment to high quality research and advancing patient care.” Jeff Greenberg, MD, Chief Medical Officer of Corrona, noted, “We believe the investment from Audax will strengthen our capabilities to generate regulatory-grade evidence on the effectiveness and long-term safety of advanced therapies for key stakeholders including patients, physicians, pharma companies, payers, and regulators.” Keith Palumbo, Managing Director at Audax Group, said, “Corrona has established itself as a gold standard provider of real-world evidence and is positioned well to expand its service offerings with additional data sources and therapeutic areas. We are excited to support Corrona as it launches new registries and continues to expand its footprint in related adjacencies, both organically and through strategic acquisitions.” Terms of the transaction were not disclosed. The Company’s HealthiVibe business complements and strengthens Corrona’s strong presence in disease registries by providing market-leading expertise in supporting innovative, evidence-based patient engagement initiatives across the product lifecycle. Through its disciplined Buy & Build approach, Audax seeks to help platform companies execute add-on acquisitions that fuel revenue growth, optimize operations, and significantly increase equity value.